Deutsche Märkte geschlossen
Nikkei 225
38.236,07 -37,98 (-0,10%) Dow Jones 30
38.225,66 +322,37 (+0,85%) Bitcoin EUR
55.349,22 +2.072,32 (+3,89%) CMC Crypto 200
1.277,42 +6,67 (+0,53%) Nasdaq Compositive
15.840,96 +235,48 (+1,51%) S&P 500
5.064,20 +45,81 (+0,91%)
Lexaria Bioscience Corp. (LEXX)
NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
Börsenschluss: 03:59PM EDT
| Kurs Vortag | 3,4900 |
| Öffnen | 3,5000 |
| Gebot | 2,5200 x 200 |
| Briefkurs | 3,0900 x 100 |
| Tagesspanne | 2,9500 - 3,5300 |
| 52-Wochen-Spanne | 0,6490 - 6,8500 |
| Volumen | |
| Durchschn. Volumen | 515.409 |
| Marktkap. | 38,399M |
| Beta (5 J., monatlich) | 0,95 |
| Kurs-Gewinn-Verhältnis (roll. Hochrechn.) | N/A |
| EPS (roll. Hochrechn.) | N/A |
| Gewinndatum | N/A |
| Erwartete Dividende & Rendite | N/A (N/A) |
| Ex-Dividendendatum | N/A |
| 1-Jahres-Kursziel | N/A |
- ACCESSWIRE
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces its intention to launch new human and animal studies to examine DehydraTECH™-processed glucagon-like peptide-1 ("GLP-1") drugs such as, but not limited to, semaglutide sold under Novo Nordisk's brand names Ozempic®, Wegovy® and Rybelsus®, for purposes of improved bioavailability, cost-effectiveness, tolerability,
